Intramammary Preparation

Bovaclox DC Intramammary Suspension is formulated for use in the dairy cow (including heifers) at the point of drying off, that is immediately after the last milking of the lactation in order to treat existing mastitis and to provide protection against further infections during the dry period. Bovaclox DC Intramammary Suspension is a useful aid in reducing the incidence of summer mastitis in dry cows at risk. Do not use on cows which have a very short dry period. Not intended for use within 45 days of calving. Milk for human consumption may only be taken from 120 hours after calving. Should a cow calve earlier than 45 days after the last treatment, milk for human consumption may only be taken from 45 days plus 120 hours after the last treatment. Active ingredient: Cloxacillin, Ampicillin

Bovaclox DC Xtra is formulated for use in the dairy cow at the point of drying off, that is, immediately after the last milking of the lactation in order to treat existing mastitis and to provide protection against further infections during the dry period. Bovaclox DC Xtra is a useful aid in reducing the incidence of summer mastitis in heifers and dry cows at risk. Do not use on cows which have a very short dry period. Not intended for use within 49 days of calving. Milk for human consumption may only be taken from 156 hours after calving. Should a cow calve earlier than 49 days after the last treatment, milk for human consumption may only be taken from 49 days plus 156 hours after the last treatment. VPA 10999/056/001. Active ingredient: Cloxacillin, Ampicillin

Boviseal is indicated for the prevention of new intramammary infections throughout the dry period. This results in a reduction in the incidence of sub clinical mastitis in cows at calving, and of clinical mastitis in the dry period and the subsequent lactation (for at least 60 days after calving). It is recommended that Boviseal be used as part of a herd approach to dry cow management and mastitis control. Cows considered likely to be free of sub clinical mastitis should be given Boviseal at drying off according to the criteria below. Other animals should be managed in accordance with an approved mastitis control plan or specific veterinary advice Active ingredient: Bismuth Subnitrate

For the treatment of clinical mastitis in the lactating cow caused by bacteria susceptible to cefquinome, namely Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, Escherichia coli. Each pre-filled syringe of 8 g contains: Cefquinome 75 mg (as Cefquinome Sulfate)

For the treatment of subclinical mastitis at drying off and the prevention of new bacterial infections of the udder during the dry period in the dairy cow caused by the following cefquinome-sensitive organisms: Streptococcus uberis, Streptococcus dysgalactiae, Streptococcus agalactiae, Staphylococcus aureus, coagulase negative staphylococci. Active ingredient: Cefquinome

Teat sealant for the prevention of new intramammary infections throughout the dry period. Active ingredient: Bismuth subnitrate heavy 2.6 gram(s)

Teat sealant for the prevention of new intramammary infections throughout the dry period. Active ingredient: Bismuth subnitrate heavy 2.6 gram(s)

Cepravin Dry Cow is a long-acting intramammary suspension containing cefalonium, a semi-synthetic cefalosporin antibiotic. VPA 10277/018/001. Active ingredient: Cefalonium

Cepravin Dry Cow is a long-acting intramammary suspension containing cefalonium, a semi-synthetic cefalosporin antibiotic. Active ingredient: Cefalonium

Cepritect is licensed for the treatment of subclinical mastitis at drying-off and the prevention of new bacterial infections of the udder during the non-lactating period of cows caused by Staphylococcus aureus Streptococcus agalactiae Streptococcus dysgalactiae Streptococcus uberis Trueperella pyogenes Escherichia coli and Klebsiella spp. susceptible to cefalonium. The long-term persistence of cefalonium in the dry udder was examined and effective levels remained up to 10 weeks after infusion.

Intramammary antibiotic cerate containing cefquinome for use in lactating cows. This product may only be prescribed by your local veterinary practitioner from whom advice should be sought. VPA 10996/105/001. Active ingredient: Cefquinome

Combiclav Lactating Cow Intramammary Suspension is specially formulated for the treatment of bovine mastitis. It contains Amoxicillin and Clavulanic Acid giving it a broad spectrum of bactericidal activity against the bacteria commonly found in the bovine udder. The prednisolone in Combiclav Lactating Cow Intramammary Suspension has an anti-inflammatory action which helps to reduce the potentially destructive swelling and inflammation associated with mastitis, without affecting the white cell response to infection. Dosage & Administration Combiclav Lactating Cow Intramammary Suspension should be administered at a dose rate of 3 syringes per infected quarter with a single syringe given every 12 hours. Use each syringe only once. Withdrawals • Milk for human consumption must not be taken from a cow during treatment. • With cows milked twice daily, milk for human consumption may only be taken from 84 hours after the last treatment. • Animals must not be slaughtered for human consumption during treatment. • Cattle may be slaughtered for human consumption only after 7 days from the last treatment.